PL1988083T3 - Pochodna triazolowa - Google Patents

Pochodna triazolowa

Info

Publication number
PL1988083T3
PL1988083T3 PL07708069T PL07708069T PL1988083T3 PL 1988083 T3 PL1988083 T3 PL 1988083T3 PL 07708069 T PL07708069 T PL 07708069T PL 07708069 T PL07708069 T PL 07708069T PL 1988083 T3 PL1988083 T3 PL 1988083T3
Authority
PL
Poland
Prior art keywords
triazole derivative
triazole
derivative
Prior art date
Application number
PL07708069T
Other languages
English (en)
Inventor
Naoya Ono
Tetsuo Takayama
Fumiyasu Shiozawa
Hironori Katakai
Tetsuya Yabuuchi
Tomomi Ota
Makoto Yagi
Masakazu Sato
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of PL1988083T3 publication Critical patent/PL1988083T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL07708069T 2006-02-03 2007-02-05 Pochodna triazolowa PL1988083T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006027799 2006-02-03
EP07708069.5A EP1988083B1 (en) 2006-02-03 2007-02-05 Triazole derivative
PCT/JP2007/051951 WO2007089018A1 (ja) 2006-02-03 2007-02-05 トリアゾール誘導体

Publications (1)

Publication Number Publication Date
PL1988083T3 true PL1988083T3 (pl) 2014-08-29

Family

ID=38327575

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07708069T PL1988083T3 (pl) 2006-02-03 2007-02-05 Pochodna triazolowa

Country Status (8)

Country Link
US (2) US8022091B2 (pl)
EP (1) EP1988083B1 (pl)
JP (1) JP5035752B2 (pl)
CN (1) CN101415691B (pl)
ES (1) ES2458615T3 (pl)
PL (1) PL1988083T3 (pl)
RU (1) RU2409570C2 (pl)
WO (1) WO2007089018A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022225B2 (en) * 2004-08-04 2011-09-20 Taisho Pharmaceutical Co., Ltd Triazole derivative
CN101415687B (zh) 2006-02-06 2012-02-08 大正制药株式会社 鞘氨醇-1-磷酸结合抑制物质
US8048898B2 (en) * 2007-08-01 2011-11-01 Taisho Pharmaceutical Co., Ltd Inhibitor of binding of S1P1
EP2262528A2 (en) * 2008-02-25 2010-12-22 Expression Drug Designs, Llc. Sphingosine 1-phosphate antagonism
US8212010B2 (en) 2008-02-25 2012-07-03 Expression Drug Designs, Llc Sphingosine 1-phosphate antagonism
EP2730579A1 (en) 2008-06-17 2014-05-14 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
AR075255A1 (es) * 2009-02-12 2011-03-16 Exelixis Inc Derivados diazolicos y/o triazolicos agonistas de receptores tgr5 acoplado a proteina g, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad, diabetes y otros trastornos metabolicos.
EP2539706B1 (en) 2010-02-24 2015-03-04 Research Triangle Institute Arylpiperazine opioid receptor antagonists
US9012443B2 (en) * 2011-12-07 2015-04-21 Amgen Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
WO2014175287A1 (ja) 2013-04-26 2014-10-30 国立大学法人 京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
HUE067028T2 (hu) * 2016-05-31 2024-09-28 Taiho Pharmaceutical Co Ltd Ribonukleotid reduktáz inhibitor szulfonamid vegyületek vagy sóik rák kezelésére
US10889555B2 (en) 2016-05-31 2021-01-12 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
MA51228A (fr) * 2017-11-29 2020-10-07 Taiho Pharmaceutical Co Ltd Agent antitumoral
ES2969901T3 (es) * 2017-11-29 2024-05-23 Taiho Pharmaceutical Co Ltd Cocristal de ácido benzoico y compuesto de sulfonamida para el tratamiento de tumores
CN111683682A (zh) 2018-02-02 2020-09-18 国立大学法人京都大学 用于预防或治疗伴有眼内血管新生和/或眼内血管通透性亢进的眼科疾病的药物
CN112142745B (zh) * 2019-06-27 2023-03-21 杭州和正医药有限公司 一种酪蛋白激酶1ε抑制剂、药物组合物及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05194412A (ja) 1991-12-28 1993-08-03 Advance Co Ltd ジアゾリン化合物
GB9202791D0 (en) * 1992-02-11 1992-03-25 British Bio Technology Compounds
JP3682075B2 (ja) * 1993-04-16 2005-08-10 クミアイ化学工業株式会社 トリアゾール誘導体及び殺虫、殺ダニ剤
DK0786455T3 (da) 1994-09-26 2004-03-29 Shionogi & Co Imidazolderivater
MY129541A (en) * 1996-06-25 2007-04-30 Novartis Ag Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
DE60134735D1 (de) 2000-04-06 2008-08-21 Astrazeneca Ab Neue neurokinin-antagonisten zum gebrauch als arzneimittel
EP1315735A4 (en) 2000-08-31 2005-04-06 Merck & Co Inc Phosphate derivatives as immunoregulatory compounds
JP2002212070A (ja) 2001-01-24 2002-07-31 Ono Pharmaceut Co Ltd アスパラギン酸誘導体を有効成分として含有するスフィンゴシン−１−リン酸拮抗剤
JP2002332278A (ja) 2001-05-08 2002-11-22 Human Science Shinko Zaidan Ｅｄｇ受容体拮抗作用を有する複素環誘導体
ES2316613T3 (es) 2001-05-10 2009-04-16 Ono Pharmaceutical Co., Ltd. Derivados de acido crboxilico y composiciones farmaceuticas que contienen los mismos como ingrediente activo.
GB0113524D0 (en) 2001-06-04 2001-07-25 Hoffmann La Roche Pyrazole derivatives
DE10130397A1 (de) * 2001-06-23 2003-01-09 Bayer Cropscience Gmbh Herbizide substituierte Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbzide und Pflanzenwachstumsregulatoren
JP4035759B2 (ja) 2001-11-06 2008-01-23 独立行政法人産業技術総合研究所 アミノアルコールリン酸化合物、製造方法、及びその利用方法
JP2005531506A (ja) 2002-03-01 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体作動薬としてのアミノアルキルホスホネートおよび関連化合物
WO2003074008A2 (en) 2002-03-01 2003-09-12 Merck & Co., Inc. Aminoalkylphosphonates and related compounds as edg receptor agonists
PT1505959E (pt) 2002-05-16 2009-02-05 Novartis Ag Utilização de agentes de ligação do receptor edg em cancro
JP2005533058A (ja) 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
US7132573B2 (en) * 2002-09-11 2006-11-07 Nippon Chemipher Co., Ltd. Amine derivative
CN100516024C (zh) * 2002-09-13 2009-07-22 诺瓦提斯公司 氨基-丙醇衍生物
DE60335827D1 (de) 2002-12-20 2011-03-03 Merck Sharp & Dohme 1-(amino)indane als edg-rezeptoragonisten
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
US7425631B2 (en) * 2003-04-10 2008-09-16 Amgen Inc. Compounds and methods of use
WO2004089367A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
AU2004240586A1 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
US8022225B2 (en) 2004-08-04 2011-09-20 Taisho Pharmaceutical Co., Ltd Triazole derivative
US20080161187A1 (en) 2005-03-16 2008-07-03 Basf Aktiengesellschaft Biphenyl-N-(4-Pyridyl) Methylsulfonamides
TW200736234A (en) 2006-01-17 2007-10-01 Astrazeneca Ab Chemical compounds
CN101415687B (zh) * 2006-02-06 2012-02-08 大正制药株式会社 鞘氨醇-1-磷酸结合抑制物质
US8097644B2 (en) * 2006-03-28 2012-01-17 Allergan, Inc. Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist
EP2013184A1 (en) 2006-04-21 2009-01-14 AstraZeneca AB Sulfonamide compounds useful as edg receptor modulators
WO2007122401A1 (en) 2006-04-21 2007-11-01 Astrazeneca Ab Imidazole derivatives for use as edg-1 antagonists

Also Published As

Publication number Publication date
ES2458615T3 (es) 2014-05-06
EP1988083A4 (en) 2009-11-11
CN101415691A (zh) 2009-04-22
EP1988083B1 (en) 2014-04-02
US20100041655A1 (en) 2010-02-18
WO2007089018A1 (ja) 2007-08-09
EP1988083A1 (en) 2008-11-05
HK1131128A1 (en) 2010-01-15
CN101415691B (zh) 2011-12-14
JP5035752B2 (ja) 2012-09-26
US20110269960A1 (en) 2011-11-03
US8022091B2 (en) 2011-09-20
RU2409570C2 (ru) 2011-01-20
RU2008135694A (ru) 2010-03-10
JPWO2007089018A1 (ja) 2009-06-25

Similar Documents

Publication Publication Date Title
HUS2400041I1 (hu) 4-Pirimidin-szulfamid-származék
IL195278A0 (en) Triazole derivatives ii
PL1988083T3 (pl) Pochodna triazolowa
LT2017278T (lt) Dihidropirazolopirimidinono darinys
EP2009005A4 (en) AZOLECARBOXAMIDE DERIVATIVE
SI1999114T1 (sl) Pirazoli kot 11-beta-hsd-1
IL202262A0 (en) Bicycloaniline derivative
ZA200901336B (en) Pyridizinone derivatives
IL195013A0 (en) Pyridopyrimidinone derivatives
IL198319A0 (en) Spiroindolinone derivatives
IL195422A0 (en) 2-pyrazinecarboxamide derivatives
IL192401A0 (en) Indol-3-yl-carbonyl-spiro-piperidine derivatives
IL196364A0 (en) Aminoindazolylurea derivatives
IL192286A0 (en) Triazole derivatives
IL193211A0 (en) Indazole-heteroaryl derivatives
EP2163554A4 (en) PYRIMIDODIAZEPINONE DERIVATIVE
EP2084135A4 (en) PYRAZOLES
ZA200904029B (en) Triazole formulation
EP2228362A4 (en) 4-HYDROXYPHENYLALKYLAMINE DERIVATIVE
ZA200807959B (en) Pyrazoles as 11-Beta-HSD-1
GB0609983D0 (en) W w w
GB0611920D0 (en) W w w
GB0609731D0 (en) W w w
GB0609838D0 (en) W w w
GB0610018D0 (en) Benzotriazepinone derivatives